

Pharmacy Formulary Updates for March 2024

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in March 2024:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Augtyro	T3;PA;SPP
Bosulif	T3;PA;SPP
Coxanto	NF
Fruzaqla	T3;PA:QL
Idose TR	Excluded
Jylamvo	NF
Ogsiveo	T3;PA;QL
Omvoh	NF;SPP
Opfolda	NF;QL
Rivfloza	NF;QL
Sohonos	T3;PA;QL
Tetracycline tablet	NF
Tramadol 25mg	NF
Truqap	T3;PA;QL
Udenyca Onbody	T3;PA;QL;SPP
Velsipity	NF;SPP
Vevye	NF;QL
Xphozah	NF
Zituvio	NF